Takeda slams NICE’s preliminary Adcetris rejection
Takeda UK says it is disappointed that cost regulators have issued a negative recommendation for Cancer Drugs Fund therapy Adcetris in relapsed or refractory Hodgkin lymphoma.
Read More
Takeda UK says it is disappointed that cost regulators have issued a negative recommendation for Cancer Drugs Fund therapy Adcetris in relapsed or refractory Hodgkin lymphoma.
Read More
